Study of the immunogenicity, safety, and tolerability of PF-05212366 in healthy toddlers aged 12 to less than 18 Months and 18 to less than 24 months

A Phase 2, Randomized, Controlled, Observer-Blinded Study Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria meningitides Serogroup B Bilvalent recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) When Administered to Healthy Toddlers Aged 12 to less than 18 Months or 18 to less than 24 Months

Category & Conditions: Vaccine-related Conditions

Medicine: PF-05212366 (Bivalent rLP2086)

ClinicalTrials.gov Identifier (NCT): NCT02534935

Protocol ID: B1971035

Print Download

Open Plain Language Summary Result: Click here